Skip to main content

Detail

Michael Bergmann
Assoc. Prof. Michael Bergmann, MD Senior PI, Colorectal Team; Head, Surgical Research Laboratories

Department of Surgery (Division of General Surgery)
Position: Associate Professor

ORCID: 0000-0001-8529-1166
T +43 1 office: 40400 73744, clinical affairs: 40400 56210
michael.bergmann@meduniwien.ac.at

Further Information

Keywords

Colorectal Neoplasms, Hereditary Nonpolyposis; Colorectal Surgery; Influenza Vaccines; Innate Immunity; Oncolytic Virotherapy; Telomere; Tumor Markers, Biological

Research group(s)

  • Applied Diagnostics
  • CCC Colorectal Unit
  • CCC Tumorimmunology
  • Colorectal Team
  • Group Bergmann
  • Ludwig Boltzmann Inst
  • Surgical Research Laboratories

Research interests

Our group focuses on the molecular understanding of cancer.  In the area of tumor immunology we investigate the induction and the consequences of immunogenic cell death. We believe that this will lead to novel concepts in immunotherapy of cancer.  We intend to learn from our patients correlating immungenic parameters of the tumor microenvironment in colorectal cancer with the course of the disease.  Having an expertise in genetic engineeing of influneza virus we developed the first oncolytic influenza virus and futher intend to optimze viral vectors and its production to allow clinical use. Our focus on an RNA viruses led to a specific interest on the impact of cell death inducing receptors in viral and malignant disease. Here we lately described novel regulatory aspects in toll-like receptor 3 signalling

Our interest in virus-cancer cell interaction also led us to the discovery that retroviral like elements such as the LINE1 retrotransposons, which comprise 17% of our genome, are involved in telomere regulation. This created a novel focus of our research on the impact of telomers and cell death.  

Techniques, methods & infrastructure

Standard molecular biology assays including qPCR, Western, ELISA, Nothern, Southern, cell culture, FACS. Qantitative Immunohistochemistry, Genetic engineering of influenza virus, molecular virology,  CRC clinical data, CRC Tumorbank 

Selected publications

  1. Hock, K. et al., 2017. Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo. Surgery, 161(3), pp.735-746. Available at: http://dx.doi.org/10.1016/j.surg.2016.08.045.
  2. Aschacher T, Wolf B, Enzmann F, Kienzl P, Messner B, Sampl S, Svoboda S, Mechtcheriakova D, Holzmann K and Bergmann M LINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines. Oncogene. 2016 Jan 7;35(1):94-104.
  3. Weiss, R. et al., 2013. IL-24 sensitizes tumor cells to TLR3-mediated apoptosis. Cell Death and Differentiation, 20(6), pp.823-833. Available at: http://dx.doi.org/10.1038/cdd.2013.15.
  4. Petricevic, B. et al., 2013. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. Journal of Translational Medicine, 11(1), p.307. Available at: http://dx.doi.org/10.1186/1479-5876-11-307.
  5. Aschacher T, Sampl S, Käser L, Bernhard D, Spittler A, Holzmann K, Bergmann M. The combined use of known antiviral reverse transcriptase inhibitors AZT and DDI induce anticancer effects at low concentrations. Neoplasia. 2012 Jan;14(1):44-53